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Background-—There is no drug therapy for abdominal aortic aneurysm (AAA). FAME-2 (Fenofibrate in the Management of
Abdominal Aortic Aneurysm 2) was a placebo-controlled randomized trial designed to assess whether administration of 145 mg of
fenofibrate/d for 24 weeks favorably modified circulating markers of AAA.
Methods and Results-—Patients with AAAs measuring 35 to 49 mm and no contraindication were randomized to fenofibrate or
identical placebo. The primary outcome measures were the differences in serum osteopontin and kallistatin concentrations
between groups. Secondary analyses compared changes in the circulating concentration of AAA-associated proteins, and AAA
growth, between groups using multivariable linear mixed-effects modeling. A total of 140 patients were randomized to receive
fenofibrate (n=70) or placebo (n=70). By the end of the study 3 (2.1%) patients were lost to follow-up and 18 (12.9%) patients had
ceased trial medication. A total of 85% of randomized patients took ≥80% of allocated tablets and were deemed to have complied
with the medication regimen. Patients’ allocated fenofibrate had expected reductions in serum triglycerides and estimated
glomerular filtration rate, and increases in serum homocysteine. No differences in serum osteopontin, kallistatin, or AAA growth
were observed between groups.
Conclusions-—Administering 145 mg/d of fenofibrate for 24 weeks did not significantly reduce serum concentrations of
osteopontin and kallistatin concentrations, or rates of AAA growth in this trial. The findings do not support the likely benefit of
fenofibrate as a treatment for patients with small AAAs.
Clinical Trial Registration-—URL: www.anzctr.org.au. Unique identifier: ACTRN12613001039774. ( J Am Heart Assoc. 2018;7:
e009866. DOI: 10.1161/JAHA.118.009866.)
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A bdominal aortic aneurysm (AAA) is a progressive weak-ening and dilatation of the infrarenal aorta that affects
2% of men and 1% of women over the age of 65 years.1–3
The most common complication of AAA is aortic rupture, and
the risk is greater at larger AAA diameters.4,5 Currently AAAs
are managed surgically; however, several large clinical trials
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have demonstrated that surgical repair does not reduce
mortality for patients with AAAs measuring <55 mm.6–10
Accordingly, surgical intervention is only recommended for
symptomatic, or large (>54 mm in men and >52 mm in
women) asymptomatic AAAs.11,12 The majority of AAAs
detected through screening programs or incidental abdominal
imaging are asymptomatic and of small diameter, and
therefore are simply monitored by repeat imaging and clinical
assessment.13,14 Up to 70% of small AAAs eventually become
symptomatic or grow to a size at which surgical intervention is
indicated.15 Effective medical therapies would enable treat-
ment of AAAs when first identified in order to prevent or limit
AAA growth and rupture.
Fenofibrate (Lipidil) is a peroxisome proliferator activated
receptor-a ligand that is used therapeutically as a lipid-
modifying agent.16 Previous rodent model studies have
demonstrated that administration of fenofibrate reduces the
severity of experimental AAA.17,18 These studies suggested
that this effect likely resulted from downregulation of
concentrations of the pro-aneurysmal protein osteopontin
within the aortas paralleled by reduced aortic inflammation
and matrix remodeling.17,18 Mice receiving fenofibrate also
had improvements in circulating lipid profiles.17 Findings
from other experimental and clinical studies suggest that
fenofibrate may also influence AAA pathology through a
range of other mechanisms including downregulation of
matrix metalloproteinase-9 (MMP-9) and resistin (discussed
in reference 13). Finally, recent human and experimental
data from our laboratory suggested that fenofibrate may
also be able to inhibit AAA pathology by upregulating the
serine proteinase inhibitor kallistatin (article currently under
review). Collectively, these data suggested that administra-
tion of fenofibrate to patients with small AAAs may block
several pathological processes implicated in AAA progres-
sion. The FAME-2 (Fenofibrate in the Management of
Abdominal Aortic Aneurysm 2) trial was designed to test
this hypothesis by randomizing patients with AAAs measur-
ing 35 to 49 mm to receive 145 mg of fenofibrate, or an
identical placebo per day for 24 weeks.19 The efficacy of
fenofibrate was primarily assessed by measuring its impact
on circulating concentrations of osteopontin and kallistatin.
Secondary outcome measures included changes in circulat-
ing lipoprotein concentrations and blood concentrations of
several proteins previously implicated in AAA (MMP-9,
D-dimer, resistin, and osteoprotegerin).20–23 Finally, we
assessed whether 24 weeks of fenofibrate reduced AAA
growth as measured by ultrasound imaging.
Methods
Requests for access to data, analytic methods, and study
materials should be made to the corresponding author.
Study Design
The full trial protocol has been previously published.19 In
brief, FAME-2 was a randomized, double-blind, multicenter,
parallel, and placebo-controlled clinical trial in which partic-
ipants were allocated to receive capsules containing fenofi-
brate (145 mg Lipidil), or inert cellulose powder (placebo)
once daily for 24 weeks. The appearance of the capsules
and associated packaging were identical for intervention and
placebo. The study included men and women aged 60 years
and above who had an AAA measuring 35 to 49 mm on
computed tomography or ultrasound, and no anticipated
requirement for AAA repair within 12 months of recruitment.
Participants were excluded if they already took fenofibrate
or related fibrates; had a known contraindication to
fenofibrate, had previous abdominal aortic surgery, had a
mycotic AAA, or if they were currently enrolled in any other
drug trial. Patients were randomized to treatment or placebo
groups on a 1:1 ratio using a computer-generated random-
ization list. Patient randomization was stratified according to
recruitment site and initial AAA diameter (35–39, 40–44,
and 45–49 mm). All patients and investigators were blinded
to treatment allocation. The study was approved by The
Prince Charles Hospital Human Research and Ethics Com-
mittee (13/QPCH/16), the Therapeutic Goods Administra-
tion (Trial number 2013/0415) and was registered with the
Australian and New Zealand Clinical Trial Registry before
commencing recruitment (ANZCTR12613001039774). All
participants provided written informed consent and the trial




• Prior preclinical research has suggested that fenofibrate
might limit the progression of abdominal aortic aneurysm
(AAA).
• This placebo-controlled randomized trial examined the
effects of 6 months fenofibrate therapy on circulating
biomarkers of AAA.
• Patients randomized to fenofibrate exhibited expected
reductions in circulating triglyceride concentrations but no
significant changes in AAA biomarkers or AAA diameter by
comparison to controls.
What Are the Clinical Implications?
• This trial suggests that fenofibrate treatment is unlikely to
have beneficial effects on AAA pathology or growth.
DOI: 10.1161/JAHA.118.009866 Journal of the American Heart Association 2


















 http://ahajournals.org by on October 1, 2018
Clinical Risk Factors and Medications
Baseline characteristics collected for each patient included
sex, age, history of hypertension, diabetes mellitus, coronary
heart disease (CHD), and prescribed medications. Diabetes
mellitus and hypertension were defined based on a previous
diagnosis and/or treatment for these conditions. Smoking
history was classified as never smoker, current smoker, or
ex-smoker (ie not having smoked within 1 month of recruit-
ment). CHD diagnosis was based on a history of angina,
myocardial infarction, or coronary artery revascularization.
Height and weight were measured in accordance with the
guidelines of the International Society for the Advancement
of Kinanthropometry. Body mass index was calculated as the
body mass in kilograms divided by the square of height in
meters.
Quality Assurance
Fenofibrate has an established ability to reduce circulating
triglyceride concentrations and is currently prescribed for this
indication.16,24 The effect of fenofibrate on triglyceride
concentration was used in addition to capsule counting as
measures of drug compliance. For the purposes of the current
study, patients were considered compliant if they had taken
≥80% of allocated capsules.
Outcome Measures
The primary outcome of the trial was the difference in
circulating concentrations of osteopontin and kallistatin
between groups during follow-up. Secondary outcomes
included differences in circulating concentrations of lipids
(high density lipoprotein-cholesterol, low-density lipoprotein-
cholesterol, very low-density lipoprotein-cholesterol, and total
cholesterol), MMP-9, resistin, osteoprotegerin, and D-dimer. A
tertiary outcome was AAA diameter.20,23,25
Blood Tests
Blood samples were collected from participants at entry, week
3, and week 24. Circulating concentrations of MMP-9,
resistin, osteoprotegerin, D-dimer, and kallistatin were mea-
sured by commercial ELISA according to manufacturers’
instructions (R&D Systems, Minneapolis, MN and Technozym,
Vienna, Austria). Reproducibility for these assays was excel-
lent (intraclass correlation 0.84–1.00) in accordance with
accepted guidelines.26 Serum concentrations of triglycerides,
high-density lipoprotein-cholesterol (HDL-C), low-density
lipoprotein (LDL)-C, homocysteine, and creatinine were mea-
sured by hospital pathology departments using automated
assays as previously described.27,28 Very low-density
lipoprotein cholesterol (VLDL-C) concentrations were esti-
mated using the formula total cholesterol—(HDL-C+LDL-C) as
previously described.27 Estimated glomerular filtration rate
(eGFR) was calculated using the Chronic Kidney Disease-
Epidemiology Collaboration group (CKD-EPI).29
Measurement of AAA Diameter
AAAs were imaged by ultrasound at entry and 24 weeks by an
experienced sonographer using a published standard proto-
col.30 Orthogonally oriented cross-sectional static images of
the infrarenal aorta obtained in the anterior–posterior plane
were acquired from the site of maximum AAA diameter. All
images were measured at the central coordinating center by 2
independent experienced readers blinded to patient allocation
using a standard protocol. For each image, 3 measurements
were made: (1) inner aortic wall to inner aortic wall; (2) leading
edge to leading edge; and (3) outer aortic wall to outer aortic
wall. The intraobserver reproducibility of the 2 observers was
assessed by repeatedly measuring scans from 50 randomly
selected patients at least 24 hours apart, with blinding to the
original readings as previously described.31 Intrarater repeata-
bility coefficients for both readers were <3 mm for each
measurement type.
Adverse Events
Adverse events (AEs) and serious adverse events (SAEs) were
defined based on guidelines published by the Australian
National Health and Medical Research Council.32 AEs and
SAEs were ascertained at 3- and 12-week phone calls and a 24-
week visit. All AEs were recorded by the trial coordinators and
reviewed by site principal investigators. All SAEs were reported
to the Human Research Ethics Committee and study sponsor.
Sample Size
Sample size calculations for this trial were determined in line
with the anticipated effects of fenofibrate on the primary
outcome measures. Previous data suggest that fenofibrate
reduces aortic osteopontin expression by 95%, and that
patients receiving fibrates for 28 days exhibit an 30%
reduction in circulating osteopontin concentrations.18,33 Col-
lectively, this led us to anticipate that 24 weeks of fenofibrate
therapy would reduce serum osteopontin concentration by at
least 30%. Pilot in vitro data led us to hypothesize that serum
kallistatin concentrations would increase by 30% in patients
allocated to fenofibrate (manuscript under review). These
effect sizes were also considered to represent a clinically
significant reduction in AAA pathology. It was hypothesized
that serum osteopontin and kallistatin concentrations would
remain unchanged in patients allocated to placebo. Assuming
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a dropout rate of 20%, sample size calculations indicated that
60 patients per group were required to demonstrate antici-
pated biomarker differences with 90% power. Since there
were 2 primary outcome measures, a 2-tailed a of 0.025 was
used in these calculations to account for multiple testing. In
May 2015 (after 50% of the planned participants had
completed the protocol), drug compliance was assessed by
capsule counting. This assessment suggested that 22% of the
patients had taken fewer than 95% of the allocated tablets, or
had withdrawn from the study. In view of this, the study
sample size was increased by 20 participants (10/group) to
minimize the risk of underpowering.
Statistical Analyses
Skewness and kurtosis tests indicated that many continuous
variables collected at baseline were not normally distributed.
Continuous baseline data are therefore presented as median
and interquartile range, and were compared between groups
using the Mann–Whitney U test. Nominal variables were
compared between groups using the v2 test (SPSS v22; IBM).
Any baseline variable with a P<0.100 following these tests was
considered to be a potential confounder. Changes in the
circulating concentrations of blood tests andAAAdiameterwere
initially compared between groups using random-intercept
Figure 1. Consolidated Standards of Reporting Trials diagram showing the flow of patients for the current
trial. SAE indicates serious adverse event.
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Table 1. Baseline Characteristics of FAME2 Participants, Separated According to Group Allocation
Characteristic Whole Cohort (n=140) Fenofibrate Group (n=70) Placebo Group (n=70) P Value*
AAA, mm
Inner-inner (observer 1) 34.7 (31.9–38.4) 34.5 (31.7–38.4) 34.8 (32.2–38.4) 0.973
Inner-inner (observer 2) 35.1 (32.3–39.0) 35.1 (32.0–39.0) 35.1 (32.5–39.0) 0.960
Leading edge-leading edge (obs 1) 37.0 (34.0–40.6) 37.0 (34.0–41.0) 37.1 (34.3–40.3) 0.877
Leading edge-leading edge (obs 2) 37.6 (34.1–40.8) 37.6 (34.1–41.3) 37.5 (34.0–40.8) 0.861
Outer-outer (observer 1) 39.7 (36.5–43.2) 39.7 (36.5–43.5) 39.4 (36.3–43.1) 0.856
Outer-outer (observer 2) 39.7 (36.0–43.1) 40.0 (36.3–43.4) 39.4 (35.7–42.8) 0.845
AAA risk factors and comorbidities
Age 76.6 (70.1–80.6) 77.1 (69.7–81.0) 76.5 (70.6–80.1) 0.965
Male sex 117 (83.6%) 59 (84.3%) 58 (82.9%) 0.820
BMI 27.0 (24.0–31.0) [1] 28.0 (24.5–32.0) [1] 27.0 (24.0–31.0) 0.447
Waist–hip ratio 0.99 (0.94–1.03) [1] 0.99 (0.95–1.05) [1] 0.98 (0.92–1.02) 0.294
Prior stroke 20 (14.3%) 12 (17.1%) 8 (11.4%) 0.334
eGFR, mL/min per 1.73 m2 72.5 (61.0–87.0) 69.5 (60.0–88.0) 73.5 (63.5–86.3) 0.809
Never smoker 18 (12.9%) 8 (11.4%) 10 (14.3%) 0.649†
Current smoker 23 (16.4%) 10 (14.3%) 13 (18.6%)
Ex-smoker 99 (70.7%) 52 (74.3%) 47 (67.1%)
Hypertension 130 (92.9%) 66 (94.3%) 64 (91.4%) 0.512
Diabetes mellitus 41 (29.3%) 23 (32.9%) 18 (25.7%) 0.353
Dyslipidemia 120 (85.7%) 57 (81.4%) 63 (90.0%) 0.147
CHD 63 (45.0%) 24 (34.3%) 39 (55.7%) 0.011‡
Peripheral artery disease 43 (30.7%) 18 (25.7%) 25 (35.7%) 0.200
Prescription for
Aspirin 86 (61.4%) 37 (52.9%) 49 (70.0%) 0.037‡
Other antiplatelet drugs 24 (17.1%) 7 (10.0%) 17 (24.3%) 0.025‡
Anticoagulants 19 (13.6%) 14 (20.0%) 5 (7.1%) 0.026‡
b-Blockers 56 (40.0%) 20 (28.6%) 36 (51.4%) 0.006‡
Calcium channel blockers 48 (34.3%) 25 (35.7%) 23 (32.9%) 0.722
Furosemide 6 (4.3%) 3 (4.3%) 3 (4.3%) 1.000
Other diuretic drugs 29 (20.7%) 12 (17.1%) 17 (24.3%) 0.297
ACE inhibitors 73 (52.1%) 37 (52.9%) 36 (51.4%) 0.866
Angiotensin receptor blockers 52 (37.1%) 25 (35.7%) 27 (38.6%) 0.726
Other antihypertensive drugs 8 (5.7%) 3 (4.3%) 5 (7.1%) 0.466
Statins 112 (80.0%) 50 (71.4%) 62 (88.6%) 0.011‡
Metformin 27 (19.3%) 16 (22.9%) 11 (15.7%) 0.284
Other oral hypoglycemic drugs 17 (12.1%) 10 (14.3%) 7 (10.0%) 0.438
Insulin 3 (2.1%) 0 (0.0%) 3 (4.3%) 0.080
Trial details
Taken ≥80% allocated medication 119 (85.0%) 57 (81.4%) 62 (88.6%) 0.237
Serious adverse events 13 (9.3%) 6 (8.6%) 7 (10.0%) 0.771
Continuous data are presented as median (interquartile range); nominal variables are presented as count and percent. Numbers in square brackets denote number of missing data points.
AAA indicates abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; BMI, body mass index; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; FAME2,
Fenofibrate in the Management of Abdominal Aortic Aneurysm trial.
*P value refers to comparisons between treatment groups using the Mann–Whitney U test (continuous variables), or v2 test (nominal variables).
†P value refers to v2 comparison of all smoking categories.
‡Potential confounders (P < 0.100 on statistical comparisons between groups).
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unadjusted linear mixed effects (LME) models (R car and nlme
packages) as previously described.34–38 In all models, time (as a
factorial variable) and allocation were treated as fixed effects,
and patients as random effects. Differences in blood markers
and AAA growth between groups were further assessed in
multivariable LME models including CHD and prescriptions
of statins, b-blockers, and antiplatelet and anticoagulant
medications (because of potential confounding) as additional
fixed effects.
For all LME models, fit was assessed through inspection of
standardized residual distribution and q-q norm plots. The
response variables were natural-log transformed to conform to
model assumptions where necessary. For all LME analyses, a
significant interaction (P<0.025) between time and treatment
allocation was considered to denote a difference between
groups. For some variables, residual plots suggested the
presence of potentially influential outliers, which may have
driven positive associations. Where this was the case, subset
analyses were performed to exclude the impact of such
outliers (defined as observations with a residual >2 standard
deviations away from the mean of model residuals) on
observed findings. Significant differences were accepted to
be true if the interaction between time and allocation was
upheld in these subset analyses. Exploratory analyses of the
primary outcome measures revealed no difference in biomar-
ker responses between recruitment centers, suggesting that
there was minimal study site bias in the current study.
All analyses were conducted by an intention-to-treat
approach using all available data. According to the study
protocol, participants were to provide 3 blood samples
(baseline and after 3 and 24 weeks), meaning a total of
420 samples were expected for analysis. Of these, 8 (1.9%)
samples were unavailable for measurements of osteopontin,
kallistatin, D-dimer, MMP-9, and resistin; and 11 (2.6%)
samples were unavailable for assessment of serum concen-
trations of cholesterol, triglycerides, homocysteine, C-reactive
protein, and creatinine. AAA diameter measurements were
unable to be performed on 3 (2.1%) patients at 24 weeks
because of their death or withdrawal from the study
(Figure 1). Missing data were not imputed because they were
not randomly distributed throughout the population, and we
have highlighted actual numbers included within both groups
at each time point. All data analyses were audited by several
authors to ensure accuracy before submission.
Results
Patient Flow
A total of 140 patients were randomized to fenofibrate or
placebo (n=70/group; Figure 1). Thirteen serious adverse
events (SAEs) were reported throughout the trial, and were
evenly distributed between groups (6 [8.6%] versus 7 [10.0%];
P=0.771, Table 1). Only 1 SAE was considered to relate to the
Table 2. Biochemical Characteristics of FAME2 Participants Separated by Group Allocation
Characteristic Whole Cohort (n=140) Fenofibrate Group (n=70) Placebo Group (n=70) P Value*
Characteristics at baseline
Total cholesterol, mmol/L 4.2 (3.6–5.0) 4.3 (3.7–5.1) 4.0 (3.4–4.7) 0.053
HDL-C, mmol/L 1.2 (1.0–1.4) 1.2 (1.0–1.4) 1.1 (0.9–1.3) 0.369
LDL-C, mmol/L 2.2 (1.8–2.8) [1] 2.3 (1.9–3.1) [1] 2.1 (1.8–2.6) 0.090
VLDL-C, mmol/L 0.7 (0.5–0.9) [1] 0.7 (0.5–0.9) [1] 0.6 (0.5–0.9) 0.309
Triglyceride, mmol/L 1.4 (1.0–1.9) 1.4 (1.1–1.9) 1.3 (1.0–1.9) 0.217
Creatinine, lmol/L 85.0 (72.3–100.0) 84.5 (71.8–103.3) 85.5 (74.5–98.5) 0.851
CRP, mg/L 2.0 (0.9–4.0) 3.0 (1.0–4.2) 2.0 (0.9–3.0) 0.059
Homocysteine, lmol/L 12.7 (10.7–15.0) 12.9 (10.7–15.7) 12.1 (10.4–14.9) 0.479
Osteoprotegerin, ng/mL 2.3 (1.8–3.1) 2.4 (1.8–3.1) 2.3 (1.9–3.0) 0.756
Osteopontin, ng/mL 62.4 (51.1–84.1) 62.1 (50.9–84.2) 62.5 (52.0–84.2) 0.654
MMP9, ng/mL 67.1 (44.0–92.7) 66.9 (47.5–91.4) 67.9 (37.5–96.1) 0.726
Kallistatin, lg/mL 11.8 (10.0–13.7) 12.0 (10.2–13.8) 11.8 (9.7–13.5) 0.717
Resistin, ng/mL 15.6 (10.1–21.0) 16.5 (9.5–22.4) 15.2 (10.6–20.0) 0.352
D-dimer, lg/mL 158.7 (103.9–262.9) 143.3 (98.1–221.0) 192.7 (115.8–292.8) 0.084
Continuous data are presented as median (interquartile range). Numbers in square brackets denote number of missing data points. CRP indicates C-reactive protein; FAME-2, Fenofibrate in
the Management of Abdominal Aortic Aneurysm 2 trial; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MMP9, matrix metalloproteinase 9; VLDL,
very low-density lipoprotein cholesterol.
*P value refers to comparisons between treatment groups using the Mann–Whitney U test.
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trial medication, which was a clinically significant decrease in
eGFR within 3 weeks of starting fenofibrate. The drug was
stopped and eGFR increased. All patients allocated fenofi-
brate were followed through to the end of the trial, although
12 (17.1%) had stopped taking the allocated intervention.
Three (4.3%) patients allocated placebo did not complete the
trial (2 withdrawals and 1 death), and an additional 6 (8.6%)
had stopped taking trial medication. In total, 137 (97.9%) of
the randomized patients were followed to the end of the trial,
and 122 (87.1%) remained on trial medication for the duration
of the study. There were no protocol violations during the trial.
Patient Characteristics
The demographic characteristics of the randomized patients
are shown in Table 1. In accordance with the study design,
patients in both groups were matched for initial AAA diameter
at recruitment (Table 1). Patients in the placebo group were
more likely to have CHD and be prescribed aspirin, other
antiplatelet medications, b-blockers, and statins, and less
likely to be prescribed oral anticoagulants. Baseline concen-
trations of total cholesterol and LDL-C were slightly lower in
the placebo group compared with those allocated fenofibrate
(Table 2). No other differences in cardiovascular risk factors
or prescribed medications were observed between groups.
Compliance
Capsule-counting data suggested that 119 (85%) patients had
adhered to the medication regimen. No significant difference in
compliance rate was observed between groups (81.4% compli-
ant in the fenofibrate group versus 88.6% in the placebo group;
P=0.237, Table 1). Serum triglyceride concentrations decreased
in participants allocated fenofibrate, and were significantly
different between groups at 3 and 24 weeks (interaction
between time and allocation P<0.001 for both time-points
following LME). eGFR was significantly lower, and circulating
homocysteine concentration higher, in patients randomized to
fenofibrate compared with those on placebo 3 and 24 weeks
after starting the allocated drug (Figure 2 and Table S1).
Effect of Fenofibrate on Serum Osteopontin and
Kallistatin Concentrations
Serum osteopontin concentrations were comparable between
groups at the time of recruitment and fluctuated over time for
all participants, although no difference in these trends was
observed between groups (Figure 3A). No difference in
circulating kallistatin concentrations were observed between
groups during follow-up (Figure 3B). Inclusion of other
covariates to adjust for potential confounders did not change
these findings (Table S1).
Effect of Fenofibrate on Other Circulating
Markers and AAA Diameter
No differences in circulating concentrations of MMP-9,
resistin, or D-dimer were found between groups (Figure 3,
Table S1). Serum osteoprotegerin concentrations appeared to
decrease over time in patients allocated fenofibrate by
Figure 2. Serum triglyceride (A), estimated glomerular filtration rate (eGFR, B), and circulating homocysteine concentrations (C) in patients
allocated fenofibrate (red circles) or placebo (blue squares) at recruitment, and after 3 and 24 weeks. Numbers of participants assessed at each
time point for each marker are shown in the respective tables. P values refer to the interaction between time and drug allocation for the follow-
up period as determined using unadjusted linear mixed effects (LME) analysis. ‡Natural log-transformed data assessed in LME. *Significant
differences between groups for that time point as assessed by LME.
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comparison to those in the placebo group, although this was
not statistically significant (P=0.095 for interaction between
time and treatment; Figure 3, Table S1). Fenofibrate reduced
serum concentrations of total cholesterol and very low-
density lipoprotein cholesterol, and these reductions
remained robust after adjusting for potential confounders
and excluding outliers (Figure 4, Table S1). Serum LDL-C and
high-density lipoprotein-cholesterol concentrations during
follow-up were similar between groups. No significant differ-
ence in AAA growth rate was observed between groups using
any of the assessed measurements (Figure 5, Table S2).
Discussion
The main finding of this study is that 24 weeks of fenofibrate
therapy did not significantly influence the circulating con-
centrations of the AAA-associated proteins that were
assessed. As would be expected from previous studies,
patients allocated fenofibrate had reductions in circulating
triglyceride concentrations and eGFR, and an increase in
serum homocysteine.16 Similarly, patients allocated fenofi-
brate experienced significant reductions in circulating con-
centrations of total cholesterol and very low-density
lipoprotein cholesterol. These findings indicate that patients
adhered to the trial protocol and that fenofibrate exerted
anticipated pharmacological effects. Examination of graphs
suggested that the serum osteoprotegerin concentration
differed between groups, although this did not reach
statistical significance. Two previous studies have investi-
gated the effect of fenofibrate on circulating osteoprotegerin
concentrations, although results from these reports were
contradictory.39,40 Syversen and colleagues reported that
plasma osteoprotegerin concentrations in rats receiving
fenofibrate were comparable to controls.40 In contrast,
Figure 3. Circulating concentrations of osteopontin (OPN A), kallistatin (B), resistin (C), osteoprotegerin (OPG D), matrix metalloproteinase-9
(MMP-9 E), and D-dimer (F) in patients allocated fenofibrate (red circles) or placebo (blue squares) at recruitment, and after 3 and 24 weeks. The
number of patients included at each time point for the markers is detailed in (G) (*D-dimer was assessed for 66 patients in the placebo group at
24 weeks). P values refer to the interaction between time and drug allocation for the follow-up period as determined using unadjusted linear
mixed effects (LME) analysis. ‡Natural log-transformed data assessed in LME. aReported P value refers to analysis of data normalized to baseline
levels to account for observed differences between groups at recruitment.
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Celinska-Lowenhoff et al reported that plasma osteoprote-
gerin concentrations significantly increased in response to
1 month of fenofibrate treatment in patients with CHD.39
Findings of the current study suggest that the trial may have
been underpowered to examine the efficacy of fenofibrate in
reducing serum osteoprotegerin concentration.
Figure 4. Serum concentrations of total cholesterol (A), high-density lipoprotein cholesterol (HDL-C, B),
low-density lipoprotein cholesterol (LDL-C, C), and very low-density lipoprotein cholesterol (VLDL-C, D) in
patients allocated fenofibrate (red circles) or placebo (blue squares) at recruitment, and after 3 and
24 weeks. The number of patients included at each time point is detailed in the corresponding tables.
P values refer to the interaction between time and drug allocation for the follow-up period as determined
using unadjusted linear mixed effects analysis. All data were natural log-transformed for analysis.
aReported P value refers to analysis of data normalized to baseline levels to account for observed
differences between groups at recruitment.
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The findings of this trial must be considered in light of its
limitations. Since AAA diameter was a tertiary outcome, it was
not the focus of the sample size calculation and the trial was
likely underpowered to assess this outcome. Despite this,
sample sizes in each treatment group of the current study
were comparable to the recently completed AARDVARK
(Aortic Aneurysmal Regression of Dilation: Value of ACE-
Inhibition on Risk) trial, in which the primary outcome was the
rate of AAA growth over 2 years.41 The possibility that
fenofibrate administration may reduce AAA growth cannot
therefore be completely dismissed and a larger trial with
longer follow-up would be required to definitively assess this.
Secondly, outcomes from this study assessed the effects of
fenofibrate on AAA pathology using concentrations of
biomarkers. It is possible that important changes in aortic
wall pathology may occur without altering these biomarkers. A
previous rodent study demonstrated that mice receiving
fenofibrate exhibited markedly fewer macrophages infiltrating
the aorta and a more preserved ultrastructure than controls.17
The possibility that fenofibrate administration leads to a
reduction in aortic inflammation and matrix remodeling is
currently being examined in the FAME trial. This randomized
control trial will assess the effects of short-term fenofibrate
therapy on pathological markers within aortic wall biopsies
collected from patients undergoing open AAA repair.42 Finally,
the possibility that a higher dose of fenofibrate might have
been effective in this trial must be considered. Participants in
the large FIELD (Fenofibrate Intervention and Event Lowering
in Diabetes) trial were allocated to receive 200 mg of
micronized fenofibrate per day. However, this has been
demonstrated to be bioequivalent to the 145 mg per day dose
used in the current study.43,44 Additionally, patients allocated
to fenofibrate in the current study exhibited expected
biochemical responses (eg reductions in serum triglyceride
concentrations). Collectively, this suggests that administering
145 mg per day of fenofibrate in this trial was an appropriate
and therapeutic dose.
In conclusion, this randomized trial found that administra-
tion of 145 mg per day of fenofibrate did not lead to reduction
in the serum concentrations of the pro-inflammatory protein
osteopontin or promote an increase in the serum concentra-
tions of the anti-aneurysmal protein kallistatin. Fenofibrate
also had no significant effect on other AAA biomarkers and
AAA growth. The findings do not support the efficacy of
fenofibrate as a therapy for patients with a small AAA.
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Table S1. Summary of outcome assessments comparing circulating biomarker concentration between groups in unadjusted, and 
adjusted LME analyses. 
Parameter assessed 
Unadjusted analyses  Adjusted analyes* 
β (std error)  
at 3 Weeks 
β (std error)  
at 24 weeks 
p-value 
β (std error)  
at 3 Weeks 
β (std error)  
at 24 weeks 
p-value 
Quality assessment 
Triglycerides† 0.277 (0.050) 0.203 (0.050) <0.001  0.278 (0.050) 0.204 (0.050) <0.001 
eGFR 12.596 (4.369) 11.727 (4.361) 0.006  12.589 (4.395) 11.722 (4.386) 0.006 
Homocysteine† -0.243 (0.041) -0.269 (0.041) <0.001  0.243 (0.041) -0.268 (0.041) <0.001‡ 
Primary outcome measures 
OPN† 0.047 (0.064) -0.022 (0.064) 0.554  0.048 (0.064) -0.021 (0.064) 0.551 
Kallistatin 0.490 (0.419) 0.324 (0.416) 0.491  0.488 (0.419) 0.322 (0.416) 0.494 
Secondary outcome measures 
MMP9† 0.082 (0.072) 0.085 (0.072) 0.406  0.082 (0.072) 0.085 (0.072) 0.405 
Resistin† -0.033 (0.054) -0.028 (0.054) 0.805  -0.032 (0.054) -0.028 (0.054) 0.809 
OPG 0.020 (0.031) 0.066 (0.031) 0.095  0.019 (0.031) 0.066 (0.031) 0.095 
Plasma D-dimer†§ 0.070 (0.074) -0.007 (0.074) 0.528  0.070 (0.074) -0.007 (0.074) 0.524 
CRP†§ 0.296 (0.166) 0.119 (0.165) 0.202  0.304 (0.166) 0.122 (0.165) 0.186 
Total cholesterol†§ 0.059 (0.023) -0.000 (0.023) 0.011‡  0.060 (0.023) 0.000 (0.023) 0.014‡ 
HDL-C† -0.009 (0.029) 0.021 (0.029) 0.576  -0.009 (0.029) 0.021 (0.029) 0.579 
LDL-C†§ 0.034 (0.037) -0.046 (0.038) 0.110  0.034 (0.037) -0.046 (0.038) 0.108 
VLDL-C†  0.270 (0.052) 0.166 (0.053) <0.001  0.271 (0.052) 0.166 (0.053) <0.001 
 
Beta coefficients refer to the interaction of time and treatment allocation (using patients allocated fenofibrate as a reference) for that time point. 
P-values relate to the interaction between time and treatment allocation over the whole 24 weeks.* Model adjusted to include history of CHD 
and prescription for statins, antiplatelet medications and anticoagulants. † Data transformed using natural log to conform to LME assumptions. ‡ 
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Table S2. Summary of models assessing differences in AAA growth between treatment groups using unadjusted and adjusted LME 
analyses.  
AAA measurement 
Unadjusted analyses  Adjusted analyses* 
β (std error) 
at 24 weeks 
p-value  
β (std error) 
at 24 weeks 
p-value 
Observer 1 
Inner-wall to inner wall 0.435 (0.398) 0.277  0.432 (0.398) 0.279 
Leading edge to leading edge 0.324 (0.327) 0.322  0.323 (0.327) 0.325 
Outer wall to outer wall 0.228 (0.313) 0.467  0.227 (0.313) 0.470 
Observer 2 
Inner-wall to inner wall 0.078 (0.359) 0.828  0.076 (0.359) 0.832 
Leading edge to leading edge 0.115 (0.342) 0.738  0.113 (0.342) 0.742 
Outer wall to outer wall -0.029 (0.327)  0.929  -0.031 (0.327) 0.925 
 
Beta coefficients refer to the interaction of time and treatment allocation (using patients allocated fenofibrate as a reference) for that time point. 
P-values relate to the interaction between time and treatment allocation over the whole 24 weeks.* Model adjusted to include history of CHD 
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